AR051754A1 - Metodos para preparar compuestos de indazol - Google Patents

Metodos para preparar compuestos de indazol

Info

Publication number
AR051754A1
AR051754A1 ARP050104568A ARP050104568A AR051754A1 AR 051754 A1 AR051754 A1 AR 051754A1 AR P050104568 A ARP050104568 A AR P050104568A AR P050104568 A ARP050104568 A AR P050104568A AR 051754 A1 AR051754 A1 AR 051754A1
Authority
AR
Argentina
Prior art keywords
prepare
methods
compound
formula
indazol
Prior art date
Application number
ARP050104568A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR051754A1 publication Critical patent/AR051754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente se refiere a la preparacion de compuestos intermedios utiles como moduladores y/o inhibidores de proteínas quinasas. Reivindicacion 1: Un método para preparar un compuesto de formula (1) o una de sus sales o solvatos farmacéuticamente aceptable, comprendiendo el método hacer reaccionar un compuesto de formula (2) con un compuesto de formula (3) para formar el compuesto de formula (1).
ARP050104568A 2004-11-02 2005-11-01 Metodos para preparar compuestos de indazol AR051754A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
AR051754A1 true AR051754A1 (es) 2007-02-07

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104568A AR051754A1 (es) 2004-11-02 2005-11-01 Metodos para preparar compuestos de indazol

Country Status (14)

Country Link
US (1) US7232910B2 (es)
EP (1) EP1809621A1 (es)
JP (1) JP2008518900A (es)
KR (1) KR20070058690A (es)
AR (1) AR051754A1 (es)
AU (1) AU2005300310A1 (es)
BR (1) BRPI0518203A2 (es)
CA (1) CA2586174A1 (es)
IL (1) IL182693A0 (es)
MX (1) MX2007005291A (es)
NO (1) NO20071619L (es)
RU (1) RU2007116107A (es)
TW (1) TWI294421B (es)
WO (1) WO2006048744A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2134702T4 (fi) 2007-04-05 2023-09-12 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
US8354528B2 (en) * 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
SG172831A1 (en) 2009-01-08 2011-08-29 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
MX2014005715A (es) 2011-11-11 2014-05-28 Pfizer N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
RU2687276C2 (ru) * 2013-12-06 2019-05-13 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные для использования в качестве ингибиторов atr киназы
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
ES2647262T3 (es) * 2014-03-31 2017-12-20 Senju Pharmaceutical Co. Ltd Derivado de alquinil indazol y uso del mismo
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
CA2989586A1 (en) 2015-06-16 2016-12-22 Pfizer, Inc. Pd-l1 antagonist combination treatments
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20220194921A1 (en) 2019-04-18 2022-06-23 Synthon B.V. Process for preparation of axitinib
WO2023166420A1 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
EP1606283B1 (en) * 2003-03-03 2008-10-08 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004226586B2 (en) 2003-04-03 2008-12-11 Pfizer Inc. Dosage forms comprising AG013736
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
NO20071619L (no) 2007-04-25
WO2006048744A1 (en) 2006-05-11
US20060094881A1 (en) 2006-05-04
US7232910B2 (en) 2007-06-19
EP1809621A1 (en) 2007-07-25
RU2007116107A (ru) 2008-11-10
KR20070058690A (ko) 2007-06-08
JP2008518900A (ja) 2008-06-05
TWI294421B (en) 2008-03-11
AU2005300310A1 (en) 2006-05-11
MX2007005291A (es) 2007-07-19
IL182693A0 (en) 2007-09-20
BRPI0518203A2 (pt) 2009-03-10
CA2586174A1 (en) 2006-05-11
TW200621721A (en) 2006-07-01

Similar Documents

Publication Publication Date Title
AR051754A1 (es) Metodos para preparar compuestos de indazol
AR061980A1 (es) Acilanilidas sustituidas y metodos para su utilizacion
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
SE0301372D0 (sv) Novel compounds
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
EA200970856A1 (ru) Ингибиторы пути хеджхога
SE0400284D0 (sv) Novel compounds
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
ECSP088296A (es) Compuestos terapéuticos
AU2012248061C1 (en) Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure